Volume | 91,634 |
|
|||||
News | (1) | ||||||
Day High | 2.20 | Low High |
|||||
Day Low | 2.01 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Hepion Pharmaceuticals Inc | HEPA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.09 | 2.01 | 2.20 | 2.01 | 2.1118 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
493 | 91,634 | $ 2.14 | $ 196,414 | - | 1.49 - 20.66 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:52:24 | formt | 500 | $ 1.3201 | USD |
Hepion Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
8.72M | 4.34M | - | 0 | -45.34M | -10.45 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Hepion Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HEPA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.27 | 2.35 | 2.00 | 2.12 | 19,968 | -0.9499 | -41.85% |
1 Month | 2.34 | 2.8999 | 2.00 | 2.40 | 31,916 | -1.02 | -43.59% |
3 Months | 1.92 | 3.4899 | 1.49 | 2.26 | 75,195 | -0.5999 | -31.24% |
6 Months | 4.37 | 5.2999 | 1.49 | 2.74 | 70,272 | -3.05 | -69.79% |
1 Year | 15.74 | 20.66 | 1.49 | 12.92 | 148,901 | -14.42 | -91.61% |
3 Years | 33.00 | 46.368 | 1.49 | 27.03 | 542,241 | -31.68 | -96.00% |
5 Years | 62.20 | 167.00 | 1.49 | 45.76 | 1,026,999 | -60.88 | -97.88% |
Hepion Pharmaceuticals Description
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. |